Nocturnal risk of gout attacks

Arthritis and Rheumatology

Volumn 67, Issue 2, 2015, Pages 555-562

  Choi, Hyon K ^a,d   Niu, Jingbo ^a   Neogi, Tuhina ^a   Chen, Clara A ^a   Chaisson, Christine ^a   Hunter, David ^b,c   Zhang, Yuqing ^a  

^a BOSTON UNIVERSITY   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALLOPURINOL; COLCHICINE; CORTICOSTEROID; DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PURINE; ANTIGOUT AGENT;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CASE STUDY; CLINICAL EVALUATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; FOOD INTAKE; GOUT; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NIGHT; OBESITY; PAIN INTENSITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEX; TIME; VERY ELDERLY; YOUNG ADULT; CASE CONTROL STUDY; CIRCADIAN RHYTHM; INCIDENCE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; FEMALE; FOLLOW-UP STUDIES; GOUT; GOUT SUPPRESSANTS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84922830075     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38917     Document Type: Article

References (31)

1. Khanna D, Khanna PP, FitzGerald JD, Singh MK, Bae S, Neogi T,. 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012; 64: 1447-61.
2. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al, for the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part II. Arthritis Rheum 2008; 58: 26-35.
3. Zhu Y, Pandya BJ, Choi HK,. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011; 63: 3136-41.
4. Choi HK, Mount DB, Reginato AM,. Pathogenesis of gout. Ann Intern Med 2005; 143: 499-516.
5. Sydenham T,. The whole works of that excellent practical physician, Dr. Thomas Sydenham: wherein not only the history and cures of acute diseases are treated of, after a new and accurate method; but also the shortest and safest way of curing most chronical diseases. Corrected from the original Latin by John Pechey in 1711. 7th ed. London: M. Wellington; 1717.
6. Abrams B,. High prevalence of gout with sleep apnea. Med Hypotheses 2012; 78: 349.
7. Roddy E, Muller S, Hayward R, Mallen CD,. The association of gout with sleep disorders: a cross-sectional study in primary care. BMC Musculoskelet Disord 2013; 14: 119.
8. Hasday JD, Grum CM,. Nocturnal increase of urinary uric acid:creatinine ratio: a biochemical correlate of sleep-associated hypoxemia. Am Rev Respir Dis 1987; 135: 534-8.
9. Sahebjani H,. Changes in urinary uric acid excretion in obstructive sleep apnea before and after therapy with nasal continuous positive airway pressure. Chest 1998; 113: 1604-8.
10. Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA,. Uric acid and oxidative stress. Curr Pharm Des 2005; 11: 4145-51.
11. Ruiz Garcia A, Sanchez Armengol A, Luque Crespo E, Garcia Aguilar D, Romero Falcon A, Carmona Bernal C, et al. Blood uric acid levels in patients with sleep-disordered breathing. Arch Bronconeumol 2006; 42: 492-500. In Spanish.
12. Plywaczewski R, Bednarek M, Jonczak L, Gorecka D, Sliwinski P,. Hyperuricaemia in females with obstructive sleep apnoea. Pneumonol Alergol Pol 2006; 74: 159-65. In Polish.
13. Plywaczewski R, Bednarek M, Jonczak L, Gorecka D, Sliwiniski P,. Hyperuricaemia in males with obstructive sleep apnoea (osa). Pneumonol Alergol Pol 2005; 73: 254-9. In Polish.
14. Chou YT, Chuang LP, Li HY, Fu JY, Lin SW, Yang CT, et al. Hyperlipidaemia in patients with sleep-related breathing disorders: prevalence and risk factors. Indian J Med Res 2010; 131: 121-5.
15. Zhang Y, Chaisson CE, McAlindon T, Woods R, Hunter DJ, Niu J, et al. The online case-crossover study is a novel approach to study triggers for recurrent disease flares. J Clin Epidemiol 2007; 60: 50-5.
16. Mittleman MA, Maclure M, Tofler GH, Sherwood JB, Goldberg RJ, Muller JE, for the Determinants of Myocardial Infarction Onset Study Investigators. Triggering of acute myocardial infarction by heavy physical exertion: protection against triggering by regular exertion. N Engl J Med 1993; 329: 1677-83.
17. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF,. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895-900.
18. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G,. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350: 1093-103.
19. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW,. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010; 62: 1060-8.
20. Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011; 306: 711-20.
21. So A, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010; 62: 3064-76.
22. Gaffo AL, Schumacher HR Jr, Saag KG, Taylor WJ, Allison J, Chen L, et al. Developing American College of Rheumatology and European League against Rheumatism criteria for definition of a flare in patients with gout [abstract]. Arthritis Rheum 2009; 60 Suppl: S563.
23. Luo X, Sorock GS,. Analysis of recurrent event data under the case-crossover design with applications to elderly falls. Stat Med 2008; 27: 2890-901.
24. Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008; 371: 205-14.
25. Li C, Ford ES, Zhao G, Croft JB, Balluz LS, Mokdad AH,. Prevalence of self-reported clinically diagnosed sleep apnea according to obesity status in men and women: National Health and Nutrition Examination Survey, 2005-2006. Prev Med 2010; 51: 18-23.
26. Pepperell JC, Ramdassingh-Dow S, Crosthwaite N, Mullins R, Jenkinson C, Stradling JR, et al. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 2002; 359: 204-10.
27. Barbe F, Duran-Cantolla J, Capote F, de la Pena M, Chiner E, Masa JF, et al. Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea. Am J Respir Crit Care Med 2010; 181: 718-26.
28. Norman D, Loredo JS, Nelesen RA, Ancoli-Israel S, Mills PJ, Ziegler MG, et al. Effects of continuous positive airway pressure versus supplemental oxygen on 24-hour ambulatory blood pressure. Hypertension 2006; 47: 840-5.
29. Maclure M,. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 133: 144-53.
30. McAlindon T, Formica M, Kabbara K, LaValley M, Lehmer M,. Conducting clinical trials over the internet: feasibility study. BMJ 2003; 327: 484-7.
31. Lorig KR, Laurent DD, Deyo RA, Marnell ME, Minor MA, Ritter PL,. Can a back pain e-mail discussion group improve health status and lower health care costs? A randomized study. Arch Intern Med 2002; 162: 792-6.